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This paper presents a retrospective comparison of plastic versus metallic stents in the drainage of malignant distal biliary
obstructions. We compared single plastic stents (SPS), multiple plastic stents (MPS), and metallic stents (SEMS) regarding
clinical decrease of TB< 2.0mg/dL, long-term patency, and adverse event. 58 patients (38 women) with MDBO were included.
Diagnoses were 44 pancreatic adenocarcinoma (74.6%), 9 metastasis (15.5%), 3 pancreatic neuroendocrine tumors (5.1%), and 2
adenocarcinoma in the major papilla (3.4%). The number of patients included in the SPS, MPS, and SEMS was 17, 6, and 35,
respectively. Comparing the survival curves with respect to obstruction, we observed a lower mean permeability of the SPS
compared to that of the MPS with p < 0 003 and of the SEMS group (p < 0 01). There was no statistical difference between the
use of MPS, despite the small number of patients compared to the use of SEMS (p < 0 13) to reach the satisfactory levels of bilirubin.
1. Introduction
Patients with malignant distal biliary obstruction (MDBO)
usually present with obstructive jaundice. These tumors
behave aggressively and develop distant metastasis in high
frequency, even in its earliest stages, thus decreasing the
chance of curative resection. Biliary drainage is indicated
to allow better life quality, usually as a palliative measure.
Biliary drainage can be achieved by surgery, percutaneous
interventions, and endoscopic retrograde cholangiopan-
creatography (ERCP). It is consensus that the most effec-
tive technique to reach biliary decompression is through
ERCP because of a better safety profile, being less likely
that complications occur. It also has a faster recovery after
drainage when compared to that of surgery. It is possible
to use plastic or metallic stents to overcome the malignant
stenosis. Variations of the technique include the use of a
single plastic stent (SPS), multiple plastic stents (MPS),
or one self-expandable metallic stent (SEMS). SPS and
MPS have mean patency time of 3 and 9 months, respectively
[1]. MPS is most indicated in cases of postsurgical benign
biliary strictures, mainly after orthotopic liver transplant.
Palliative or neoadjuvant chemotherapy has better results
when there is no biliary obstruction because most of the
chemotherapeutic agents are hepatotoxic. The association
of oxaliplatin, 5-fluoracil, leucovorin, and irinotecan (FOL-
FIRINOX) is the palliative regimen that carries the best
long-term survival in these patients but has the major side
effect of causing steatohepatitis and periportal fibrosis with
hepatic failure if the patient keeps jaundiced. Thus to
decrease complication rate and improve efficacy, total biliru-
bin (TB) levels should be under 2.0mg/dLprior to chemother-
apy. When this TB level is not reached, alternative regimens
using oxaliplatin without irinotecan or gemcitabine are
available, but results are not as good as for FOLFIRINOX.
The authors demonstrate and evaluate which endoscopic
technique is the best to achieve satisfactory TB to start chemo-
therapy in patients with MDBO, to provide improvements in
Hindawi
Gastroenterology Research and Practice
Volume 2017, Article ID 7621821, 6 pages
https://doi.org/10.1155/2017/7621821
life quality. There is only one reference in the literature in
regard to this theme, and this is the reason for this study to be
published [2]. Themain objective of this study was to evaluate
and compare which technique of biliary stent interposition/
implant (SPS, MPS, or SEMS) would be the best option to
decrease TB levels under 2.0mg/dL thus allowing the use of
chemotherapy without restrictions.
2. Methods
Patients diagnosed with MDBO, submitted to biliary drain-
age through ERCP in the AC Camargo Cancer Center, São
Paulo, Brazil, from January to December of 2015, were
followed and their medical record revised from the staging
diagnosis indicating endoscopic drainage until a new biliary
obstruction occurred or death. We evaluated the clinical
decrease of TB< 2.0mg/dL, time to reach this level, long-
term patency (time from intervention until obstruction or
death) determined by increment in TB, need for new drain-
age, or occurrence of adverse event related to insufficient
biliary drainage. We considered stent disfunction when any
of the fallowing circumstances happened: jaundice recur-
rence, cholangitis, or asymptomatic raising in the hepatic
enzymes, bilirubins, and ductal enzymes in conjunction.
2.1. Inclusion and Exclusion Criteria. We included patients
diagnosed with MDBO by computed tomography (CT)
and/or magnetic resonance (MR) not amenable to surgery
and with life expectancy≥ 4 months. We excluded those
with previous biliary drainage, initial TB≤ 2.0mg/dL, and
synchronic hilar strictures.
2.2. Endoscopic Biliary Drainage. All procedures were per-
formed by experienced endoscopists (ET and AMS). We
used straight plastic stents of 8.5 and 10 Fr (Cotton-Leung®
Cook Medical, Limerick, Ireland) and metallic stents of
10mm of diameter (WallFlex Biliary RX® Boston Scientific,
Marlborough, Massachusetts, USA). The choice among SPS,
MPS, and SEMS was left at the endoscopist’s discretion. We
compared three groups: group 1 (SPS), group 2 (MPS), and
group 3 (SEMS).
2.3. Clinical Success, Adverse Events, and Follow-Up. Clinical
success was considered when the TB level decreased below
2.0mg/dL within the same hospital stay and unsuccessful
when they do not. After initial treatment failure, the patients
were submitted to one of the following: new endoscopic
drainage, percutaneous drainage, or surgical drainage. Early
adverse events (within 7 days) were registered and studied
as well as the late ones (after 7 days of intervention). Their
treatment was chosen and the results were also evaluated.
Our routine for patients with MDBO unfit for surgical
resection is endoscopic drainage and palliative chemotherapy
within the same hospital stay. On the first week, BT was con-
trolled daily. After this period, BT levels were measured
weekly during the chemotherapy cycles or according to the
assisting clinical oncologist discretion, based on patients’
clinical findings.
2.4. Statistical Analysis. The differences on demographic
characteristics among groups SPS, MPS, and SEMS were
made using independence analysis. Age comparison was
made by the Kruskal-Wallis method and the qualitative
variables by the Fisher’s exact test. Patency time of stents
used in each group was evaluated using the Kaplan-Meier
survival curve, and a comparison among each other was
made with the Mantel-Cox log-rank method. Stent patency
time was considered the period from intervention until stent
dysfunction or death.
3. Results
After applying exclusion criteria, 58 patients with MDBO
were included in the final analysis. A total of 82 ERCP,
median 1.4 procedure per patient (1–4), were made. There
were 20 men and 38 women, with the median age of 64.5 y
old (17–96). Final diagnoses were the following: 44 pancreatic
adenocarcinoma (74.6%), 9 metastasis (15.5%), 3 pancreatic
neuroendocrine tumors (5.1%), and 2 adenocarcinoma of
the major duodenal papilla (3.4%).
The 3 groups were separated and evaluated according to
drainage technique previously described in these study
methods. Therewas no significant statistical difference among
groups related to sex, age, and indications. Demographic data
and indications separated by groups are shown on Table 1.
3.1. Group Analysis
3.1.1. Single Plastic Stent (SPS). Seventeen patients received
this type of treatment. There were inserted with 10 Fr
(14 (82%)) and 8.5 Fr (3 (18%)) stents. The mean patency
was 70.5 (2–213) days. Clinical failure (total bilirubin remai-
ning>2mg/dL)was observed in 11 (64%)patients.NewERCP
was indicated in 9 (81.8%) and 2 (18.2%) patients were
referred for percutaneous biliary drainage. The overall rate of
adverse events was 5/17 (29.4%). Early adverse events (up to
7 days) were identified in 3/17 (17.6%) patients (cholangitis
(1), bleeding (1), and acute pancreatitis (1)). Cholangitis was
the most frequent late adverse event, occurring in 2/17
(11.7%). All identified adverse events was treated conserva-
tively. The 3 patients with cholangitis were treated by endos-
copy, and patients with acute pancreatitis and bleeding were
identified asmild and/or self-limited, requiring no endoscopic
or surgical intervention.
3.1.2. Multiple Plastic Stents (MPS). This group consisted of 6
patients. The average number of stents used per patient was
2.5 (2-3), varying between 7Fr (8), 8.5 Fr (4), and 10Fr (3).
The mean permeability time was 297 (3–534) days. Clinical
failure occurred in 1 (16.6%) patient. The overall rate of
adverse events was 1/6 (16.6%) patients, being the same
patientwith clinical failure. This patient had cholangitis 4 days
after the procedure and percutaneous drainage was indicated.
3.1.3. Self-Expandable Metallic Stent (SEMS). Thirty-five
patients underwent SEMS insertion. SEMS used were par-
tially covered (20), uncovered (10), and totally covered (5).
The mean SEMS patency was 190 (3–586) days. Clinical fail-
ure occurred in 10 (29%) patients. The overall rate of adverse
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events was 8.5% (3/35). Mild bleeding occurred in 2 (5.6%)
and cases and acute pancreatitis in 1 (2%). All occurred within
7 days of the procedure. All were treated conservatively.
3.2. Comparison between Clinical Success and Survival. The
mean initial bilirubin level was 11.71mg/dL (2.03–31.5),
which was distributed as follows: SPS (14.22mg/dL), MPS
(11.32mg/dL), and SEMS (9.61mg/dL) with p < 0 005. The
percentage of patients who reached the target bilirubin level
and the mean time in days to reach this target in the SPS,
MPS, and SEMS groups were 35% (16.6 days), 85% (38.4
days), and 71% (19.52 days), respectively, with p < 0 005.
The success rate in achieving BT<2mg/dL for SEMS,
MPS, and SPS was 68.5% (24/35), 83.3% (5/6), and 41.1%
(7/17), respectively. Although there was mainly divergence
between SPS and MPS and SEMS, this difference was not
significant (p < 0 093) (Table 2).
Comparing the survival curves with respect to obstruc-
tion, we observed a lower mean permeability of the SPS
compared to the MPS with p < 0 003 and in relation to the
SEMS group (p < 0 01) (Figures 1 and 2). However, when
MPS versus SEMS was evaluated, no statistically significant
difference was observed (p < 0 134) (Figure 3). There was
no difference in the rate of fall of total bilirubin in those
who reached TB<2mg/dL regardless of the method used
(p < 0 639) (Figure 4).
4. Discussion
The main cause of malignant biliary obstruction is pancreatic
cancer. Of these patients, only 15 to 20% can be operated
after staging obtained CT or MRI, and even after surgery,
the 2-year survival varies around 10 to 20% [3, 4]. Pancreatic
cancer is the fifth leading cause of death according to the
CDC [5]. Those that can not be operated need palliative
treatment to control complications inherent of the locoregio-
nal disease progression. Endoscopic biliary drainage is the
principal method of treating jaundice in these patients [6, 7].
The main benefits of biliary drainage are relief of jaun-
dice and allowance to chemotherapy in good clinical
conditions. Most of the used regimens have hepatotoxic
drugs, which can induce steatohepatitis or sinusoidal
obstruction [8–10]. To be used to its full potential, it is
necessary that the total bilirubinemia is up to 1.5 times
above the normal value [11]. The choice of the TB
limit<2.0mg/dL as a mark of therapeutic success reflects
the aggressive need to ensure good biliary drainage in rela-
tion to what the current chemotherapy regimens demand.
However, the benefit of using bile duct stents is limited
due to the occurrence of stent obstruction, patency time
of the stent with worsening of jaundice, presence of
cholangitis, and time (speed) for TB to reach adequate
levels for initiation of chemotherapy on its full potential.
Our sample is comprised of patients with pancreatic
adenocarcinoma (74.6%), metastasis (15.5%), and pancre-
atic neuroendocrine tumors (5.1%). Similar numbers have
already been reported in the literature, corroborating the
representativeness of our sample. The global percentage
of patients who achieved the bilirubinemia target was
37.9%. This value differs from that previously found by
Weston et al. of 76.2% when only patients with adequate
follow-up were included in their series [2]. Observing
only those with SEMS and MPS, the clinical success rate
rises to 71% and 85%, respectively, and there is an
apparent improvement in outcome (p = 0 09) (Table 2).
Although the knowledge that such low levels of bilirubinemia
Table 1: Demographic findings of the patients and the etiological cause of MDBO.
Demographic findings G1 (SPS) G2 (MPS) G3 (SEMS) Total p
Number of patients 17 6 35 58 —
Mean age 59.35 (15.51) 67.3 (4.59) 67.04 (10.28) 0.23
Gender (M/F) 8/9 2/4 10/15 0.99
Type of obstruction — — — — —
Pancreatic cancer 11 4 29 44 0.52
Neuroendocrine tumor 2 0 1 3 0.46
Papillary carcinoma 0 1 1 2 0.99
Metastasis — — — — —
Colon 2 1 2 5 0.46
Lung 0 0 1 1 0.99
Kidney 0 0 1 1 0.99
Rhabdomyosarcoma 1 0 0 1 0.36
Ovary 1 0 0 1 0.36
Table 2: Cross tabulation comparing therapeutic success between
groups (p < 0 093).
TB≤ 2mg/dL Yes (%) No (%) Total (%)
G1 (SPS) 7 (19.4) 10 (45.5) 17 (29.3)
G2 (MPS) 5 (13.9) 1 (4.5) 6 (10.3)
G3 (SEMS) 24 (66.7) 11 (50) 35 (60.3)
Total 36 22 58
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are required for chemotherapy [11, 12], there is little refer-
ence in the literature to the quantity/percentage of patients
achieving such a target. The only source that evaluates the
time required to reach the proposed target is a study by
Weston et al. [2] which evaluates the time it takes for 80%
of patients to reach the target of 2mg/dL. In this study, it
is shown that patients with initial TB of less than 10mg/dL
usually take 2.7 weeks to reach the target and the same value
for those with initial TB above 10mg/dL is 5.6 weeks. The
same work shows that the rate of fall of TB is independent
of the chosen drainage method, which was corroborated by
our casuistry.
The use of SEMS is more durable and requires fewer
reinterventions when compared to the use of biliary drainage
with SPS. While the use of SPS has an estimated mean
permeability of 90 to 120 days, this estimate increases to
240–270 days for SEMS [13–16]. The main cause of
p< 0.001
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Figure 1: Comparison of the permeability time of patients
undergoing SPS and MPS insertion (p < 0 001).
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Figure 2: Comparison of the permeability time of patients
undergoing SPS and SEMS insertion (p < 0 001).
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Figure 3: Comparison of the permeability time of patients
undergoing MPS and SEMS insertion (p = 0 13).
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Figure 4: Comparison among the three groups in relation to the
time in days to reach TB≤ 2.0mg/dL.
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obstruction in cases of SPS is the accumulation of debris in its
interior, this being credited to its smaller diameter and the
bacterial colonization that adheres to the internal wall of
the stent when compared to SEMS. Hausegger et al., using
SEMS, reported an occlusion rate of 33% with fully covered
stent, but without a statistical difference between covered
and uncovered [17]. The incidence of early obstruction is
common among SPS plastic stents [1, 17, 18], which is a
critical factor in choosing the drainage method in a patient
who will receive chemotherapy with risks of hepatic failure
or severe septic complications. In our study, the worst results
regarding survival until stent obstruction were related to the
use of SPS. We adopt an on demand regimen of sten
exchange in patients with MDBO to avoid unnecessary pro-
cedures and hospital staying.
Several unsuccessful attempts were made to improve SPS
drainage from higher caliber stents to stents with different
formats [19, 20]. Tabibian et al. have shown that there is a
bile flow between the stents when MPS are applied, even
when some or all of them are obstructed [21]. In this same
study, the author verified that the use of MPS allows a longer
time of permeability, reducing the need for repeated
endoscopic interventions in biliary stenoses after hepatic
transplantation, but there is no evidence of this assertion in
patients with malignant disease, which further corroborates
the value of this presented study.
Lawrence et al. similarly obtained a longer permeability
time by applying MPS (2 stents) in stenosis after surgery
[22]. Despite this knowledge about MPS in benign stenoses,
there is only one report of MPS in patients with MDBO, in
which two prostheses were applied increasing the permeabil-
ity time [23]. There are no data in the literature that compare
the application ofMPS to other endoscopic drainagemethods.
The application of MPS in our evaluation proved effec-
tive. The combination of mean patency was similar to that
of SEMS and the reduced cost of using MPS allows us to
think of this as the best form of biliary drainage. The fact that
there was no statistical difference in speed (time) to reach
TB<2mg/dL among groups is in line with previous research
showing similarity in drainage quality among methods in the
first month [24]. However, the use of TB<2mg/dL as the
object of evaluation reflects in a practical way the current
need that a patient with MDBO has.
There are several limitations in the present study mainly
due to its retrospective nature. The groups were uncon-
trolled, with a small sample in the SPS and MPS arms and
the study was from a single center.
The rate of adverse events found, although similar to that
reported in other studies, may be underestimated because of
the retrospective nature of the study [1]. Another weakness
of this study is the reduced number of patients in the SPS
and MPS groups. The application of MPS in our institution
is an exception being applied according to the preference of
the endoscopist at the time of the procedure.
Based on the results of this study, the authors conclude
that endoscopic biliary drainage is effective and presents a
low rate of adverse events. The use of SPS was not effective
in achieving the total bilirubin levels desired for chemother-
apeutic treatment, and there was no statistical difference
between the use of MPS, despite the small number of patients
compared to the use of SEMS to reach satisfactory levels of
bilirubin for the chemotherapeutic treatment, thus determin-
ing that the use of both SEMS and MPS can be performed in
patients with MDBO.
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